AlphaStocks
6.4
Consider Buy

CATALYST PHARMACEUTICALS, INC. (CPRX)

Health Care / Biotechnology

S&P SmallCap 600

$24.83

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#197out of 1127 in Health Care

Is CATALYST PHARMACEUTICALS, INC. a Good Investment in 2026?

CATALYST PHARMACEUTICALS, INC. (CPRX) scores 6.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Lynch model rates CATALYST PHARMACEUTICALS, INC. as Strong (PEG 0.3 · Fast Grower). The Graham model is the least favorable, rating it Neutral. CATALYST PHARMACEUTICALS, INC. ranks #197 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E14.7ROE22.9Market Cap3B

Valuation

Trades at 15x earnings — near sector median of 25x.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

41% above fair value

Lynch

Strong

PEG 0.3 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is CATALYST PHARMACEUTICALS, INC. (CPRX) a good investment?
Based on AlphaStocks' composite analysis, CATALYST PHARMACEUTICALS, INC. (CPRX) scores 6.4 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trades at 15x earnings — near sector median of 25x.
What is CATALYST PHARMACEUTICALS, INC.'s Piotroski F-Score?
CATALYST PHARMACEUTICALS, INC.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CPRX overvalued or undervalued?
A precise fair value estimate is not available for CPRX. Trades at 15x earnings — near sector median of 25x.
How does CPRX compare to other Health Care stocks?
CATALYST PHARMACEUTICALS, INC. ranks #197 out of 1127 stocks in the Health Care sector, placing it in the top 17% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about CPRX?
AlphaStocks evaluates CPRX using five proven investment models. Piotroski: Neutral; Buffett: Attractive; Graham: Neutral; Lynch: Strong. These models are combined into a single composite score of 6.4/10.

Similar Stocks

PARRFTIAZN

Compare CPRX with

CPRX vs PARRCPRX vs FTICPRX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer